^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Excerpt:
...- Patients with histologically or cytologically confirmed metastatic left-sided colorectal adenocarcinoma with wild-type RAS and BRAF genes;...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

First-line treatment of mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS/BRAF genes: a multicenter, randomised, phase 2 study

Excerpt:
...Patients with histologically or cytologically confirmed metastatic left-sided colorectal adenocarcinoma with wild-type RAS and BRAF genes; 4. ...
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A real-world retrospective study to evaluate the reliability of cetuximab plus capecitabine versus capecitabine as maintenance therapy in patients with RAS and BRAF wild-type metastatic colorectal cancer

Published date:
09/20/2023
Excerpt:
In this retrospective analysis, patients with RAS and BRAF mCRC admitted to the Department of Medical Oncology, Huizhou Municipal Central Hospital, from January 2016 to October 2020 were enrolled and treated with cetuximab plus FOLFIRI as an initial therapy....The median PFS after maintenance treatment in observation group (9.5 months, [95% CI=6.4-12.6]), was significantly better than the control group (7.3 month, [95% CI=5.8-8.8]).
Secondary therapy:
FOLFIRI
DOI:
10.1159/000533528
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial

Excerpt:
This trial evaluated the addition of cetuximab to a modified FOLFOXIRI (mFOLFOXIRI: 5-fluorouracil/folinic acid, oxaliplatin, irinotecan) as conversion therapy in a two-group, nonrandomized, multicenter, phase II trial in patients with initially technically unresectable colorectal liver-limited metastases (CLM) and BRAF/RAS wild-type...Patients in the cetuximab group had improved ORR (95.5% vs. 76.5%; difference 19.1%; 95% CI, 17.4%-36.4%; p = .010) compared with those in control group. Progression-free survival and overall survival showed the trend to favor the cetuximab group.
Secondary therapy:
FOLFOXIRI
DOI:
10.1634/theoncologist.2020-0563